VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MEDS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MEDSDataMEDS AI, Inc.
$0.73$5M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. MEDS
  4. Financial Ratios

DataMEDS AI, Inc. (MEDS) Financial Ratios

Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE N/A. (2023–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

MEDS Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023
Market Cap$5M$28M——
Enterprise Value$30M$53M——
P/E Ratio →-0.12———
P/S Ratio0.691.22——
P/B Ratio————
P/FCF————
P/OCF————

P/E links to full P/E history page with 30-year chart

MEDS EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023
EV / Revenue—2.27——
EV / EBITDA————
EV / EBIT————
EV / FCF————

MEDS Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023
Gross Margin-41.3%-41.3%9.7%—
Operating Margin-347.9%-347.9%-33.9%—
Net Profit Margin-433.9%-433.9%-37.8%—

Return on Capital

MetricTTMFY 2025FY 2024FY 2023
ROE——-357.7%—
ROA-230.7%-230.7%-23.8%-855.8%
ROIC-282.6%-282.6%-32.2%—
ROCE-813.4%-813.4%-73.4%—

MEDS Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023
Debt / Equity——3.73—
Debt / EBITDA————
Net Debt / Equity——3.58—
Net Debt / EBITDA————
Debt / FCF————
Interest Coverage-21.11-21.11-7.25-191.01

MEDS Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023
Current Ratio0.090.090.400.12
Quick Ratio0.040.040.150.12
Cash Ratio0.000.000.030.00
Asset Turnover—0.770.32—
Inventory Turnover20.1120.111.72—
Days Sales Outstanding—17.7975.42—

MEDS Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023
Dividend Yield————
Payout Ratio————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023
Earnings Yield————
FCF Yield————
Buyback Yield0.0%0.0%——
Total Shareholder Yield0.0%0.0%——
Shares Outstanding—$1M$1M$894400

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Negative equity with persistent burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Sub-Unity Sales Multiple Reflects Distress

Based on the supplied valuation data, MEDS trades at a P/S of 0.33 while P/E is negative at -0.06, leaving earnings-based multiples uninformative and pricing driven almost entirely by revenue expectations.

A price-to-sales ratio of 0.33 typically signals that the market assigns limited value to current revenue, which is consistent with quarterly sales falling from $12.4M to $1.6M over the observed period. The negative P/E of -0.06 is not meaningful as a valuation anchor because it reflects a sign flip from negative trailing earnings rather than a cheap earnings yield. Investors should monitor whether the sub-unity sales multiple reflects a durable discount or a market view that current revenue is not sustainable.

Operating Losses Persist Across Quarters

As reported in the ratio series, operating margin ranged from -126.4% in 2026Q3 to -2.9% in 2025Q1, and gross margin turned negative at -9.8% in 2026Q2, showing no sustained path to profitability.

Operating margins have remained negative in every one of the ten quarters, with the extreme -126.4% in 2026Q3 suggesting that cost structure is large relative to a shrinking revenue base. The swing in gross margin from 13.4% in 2024Q2 to negative values indicates direct costs have at times exceeded revenue, which points to pricing or cost-of-service pressure rather than purely overhead. The positive 2026Q3 net margin of 4.0% appears inconsistent with the operating loss and may reflect non-operating or non-recurring items that warrant further investigation before being treated as earning power.

ROIC Remains Deeply Negative Throughout

Based on reported figures, ROIC has been negative in all ten quarters, reaching -87.5% in 2025Q3 and -16.7% in 2026Q3, indicating that invested capital has not generated any return across the observed period.

A consistently negative ROIC means the company has been destroying value on its invested capital base rather than compounding it, a pattern driven by operating losses rather than capital structure alone. The ROE readings are distorted by the negative equity base, so the 61.7% figure in 2026Q3 reflects a small or negative denominator and should not be read as genuine improvement. Investors should treat the return metrics as signaling capital inefficiency until operating margins turn positive.

Negative Equity Inflates Leverage Ratios

According to the reported statements, D/E stood at 116.15 in 2026Q3 against a current ratio of 0.14, and interest coverage remained negative at -1.50, indicating that debt service is not covered by operating earnings.

The D/E of 116.15 reflects a near-zero or negative equity denominator rather than a moderate debt load, so the ratio is directionally alarming but mathematically unstable. Interest coverage below zero indicates operating income does not cover interest expense, a condition that may raise refinancing risk if creditors reassess the business. Covenant terms are not included in the supplied data, so the severity of this exposure cannot be fully assessed from these figures alone.

Thin Liquidity Buffer Against Obligations

Based on EDBL-style reported figures, the current ratio fell to 0.14 in 2026Q3 and quick ratio to 0.10, indicating that liquid assets cover only a small fraction of short-term obligations.

A current ratio of 0.14 and quick ratio of 0.10 suggest that current liabilities are many multiples of readily available resources, leaving little room to absorb an adverse operating or financing event. The gap between current and quick ratios is narrow, implying limited dependence on inventory, though the cash conversion cycle of -328 days indicates heavy reliance on supplier financing that could reverse. Under severe stress, the position would likely require external capital or payment term renegotiation, though the supplied data does not disclose specific facility access.

D/E Misleads Under Negative Equity

As reported in the ratio series, the D/E ratio of 116.15 in 2026Q3 is the metric most commonly misapplied here, because with negative equity it obscures the true debt burden rather than measuring it.

When equity is negative, D/E loses its ordinary meaning, and a rising or falling figure can reflect equity movements rather than changes in debt, so trend reads can be misleading. A more informative approach is to examine total debt against operating cash flow or EBITDA, alongside interest coverage, since the supplied operating and cash flow data show cash burn that debt service must ultimately draw upon. Investors should weigh debt-to-operating-cash-flow and liquidity runway over headline D/E when assessing solvency.

Download Financial Ratios Data

Includes 30+ ratios · 3 years · Updated daily

Consensus & Technical Research Suite
Open MEDS Terminal

MEDS Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

MEDS — Frequently Asked Questions

Quick answers to the most common questions about buying MEDS stock.

What is DataMEDS AI, Inc.'s P/E ratio?

DataMEDS AI, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.

Is MEDS stock overvalued?

Based on historical data, DataMEDS AI, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are DataMEDS AI, Inc.'s profit margins?

DataMEDS AI, Inc. has -41.3% gross margin and -347.9% operating margin.